Letter | Published:

The mechanism of Z α1-antitrypsin accumulation in the liver

Abstract

MOST northern Europeans have only the normal M form of the plasma protease inhibitor α1,-antitrypsin, but some 4% are heterozygotes for the Z deficiency variant1. For reasons that have not been well-understood, the Z mutation results in a blockage in the final stage of processing of antitrypsin in the liver2such that in the Z homozygote only 15% of the protein is secreted into the plasma. The 85% of the α1, -antitrypsin that is not secreted accumulates in the endoplasmic reticulum of the hepatocyte; much of it is degraded but the remainder aggregates to form insoluble intracellular inclusions. These inclusions are associated with hepatocellular damage, and 10% of newborn Z homozygotes develop liver disease which often leads to a fatal childhood cirrhosis. Here we demonstrate the molecular pathology underlying this accumulation and describe how the Z mutation in antitrypsin results in a unique molecular interaction between the reactive centre loop of one molecule and the gap in the A-sheet of another. This loop–sheet polymerization of Z antitrypsin occurs spontaneously at 37 °C and is completely blocked by the insertion of a specific peptide into the A-sheet of the antitrypsin molecule. Z antitrypsin polymerized in vitro has identical properties and ultra-structure to the inclusions isolated from hepatocytes of a Z homozygote. The concentration and temperature dependence of this loop–sheet polymerization has implications for the management of the liver disease of the newborn Z homozygote.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Laurell, C. B. & Eriksson, S. Scand. J. clin. Lab. Invest. 15, 132–140 (1963).

  2. 2

    Carrell, R. W. J. clin. Invest. 78, 1427–1431 (1986).

  3. 3

    Huber, R. & Carrell, R. W. Biochemistry 28, 8951–8956 (1989).

  4. 4

    Carrell, R. W. & Evans, D. LI. & Stein, P. E. Nature 353, 576–578 (1991).

  5. 5

    Evans, D. LI. thesis, Univ. Cambridge (1991).

  6. 6

    Schulze, A. J. et al. Eur. J. Biochem. 194, 51–56 (1990).

  7. 7

    Curiel, D. T. et al. J. biol. Chem. 264, 13939–13945 (1989).

  8. 8

    Seyama, K. et al. J. biol. Chem. 266, 12627–12631 (1991).

  9. 9

    Stein, P. & Chothia, C. J. molec. Biol. 221, 615–621 (1991).

  10. 10

    Eriksson, S. & Larsson, C. New Engl. J. Med. 292, 176–180 (1975).

  11. 11

    Bathurst, I. C., Travis, J., George, P. M. & Carrell, R. W. FEBS Lett. 177, 179–183 (1984).

  12. 12

    Cox, D. W., Billingsley, G. D. & Callahan, J. W. FEBS Lett. 205, 255–260 (1986).

  13. 13

    Le, A., Ferrell, G. A., Dishon, D. S., Quyen-Quyen, A. L. & Sifers, R. N. J. biol. Chem. 267, 1072–1080 (1992).

  14. 14

    Carlson, J. A. et al. J. clin. invest. 83, 1183–1190 (1989).

  15. 15

    Laurell, C. B., Pierce, J., Persson, U. & Thulin, E. Eur. J. Biochem. 57, 107–113 (1975).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.